Skip to content

Vestal Point Capital, LP

Follow

13F filer, CIK 1974915, NEW YORK, NY

Vestal Point Capital, LP reported $3,870,755,286 across 63 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 67.29% of the portfolio.

Accepted , ingested 13F-HR 0001974915-26-000008

Period
2026-09-30
Reported value
$3.87B
Holdings
63
Top 10 weight
67.29%
New
15
Sold out
20

Part of the filer group Vestal Point Capital, LP

  • Ryan Wilder
How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
INSMadded+2,475,000$282M
ARWRadded+3,240,000$212M
ABVXadded+1,610,557$159M
NBIXadded+620,000$87.9M
ASNDadded+365,000$83.2M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ABTexited-1,400,000-$127M
AZNexited-450,000-$85.3M
RVMDexited-450,000-$84.3M
BCRXexited-8,300,000-$83M
ZBHreduced-925,000-$82.2M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001974915-26-000008, largest first. % of portfolio is the value over $3,870,755,286, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,000,000 shares; 2025Q4: 1,900,000 shares; 2026Q1: 1,500,000 shares; 2026Q2: 2,349,443 shares; 2026Q3: 3,960,000 shares 3,960,000$392M10.13%+1,610,557Timeline
NBIXNEUROCRINE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 30,000 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,250,000 shares; 2026Q2: 1,880,000 shares; 2026Q3: 2,500,000 shares 2,500,000$355M9.16%+620,000Timeline
BMRNBIOMARIN PHARMACEUTICAL INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 860,000 shares; 2025Q1: not reported; 2025Q2: 500,000 shares; 2025Q3: 830,000 shares; 2025Q4: 3,000,000 shares; 2026Q1: 3,575,000 shares; 2026Q2: 6,025,000 shares; 2026Q3: 5,525,000 shares 5,525,000$332M8.56%-500,000Timeline
ARWRARROWHEAD PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 900,000 shares; 2026Q1: 2,275,000 shares; 2026Q2: 1,575,000 shares; 2026Q3: 4,815,000 shares 4,815,000$315M8.14%+3,240,000Timeline
INSMINSMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 900,000 shares; 2025Q1: 1,075,000 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 250,000 shares; 2026Q3: 2,725,000 shares 2,725,000$311M8.04%+2,475,000Timeline
UTHRUNITED THERAPEUTICS CORP DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 75,000 shares; 2026Q2: 435,000 shares; 2026Q3: 475,000 shares 475,000$257M6.65%+40,000Timeline
ASNDASCENDIS PHARMA A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 375,000 shares; 2026Q3: 740,000 shares 740,000$169M4.36%+365,000Timeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 485,000 shares; 2025Q1: 1,125,552 shares; 2025Q2: 2,000,000 shares; 2025Q3: 3,475,000 shares; 2025Q4: 4,690,000 shares; 2026Q1: 6,500,000 shares; 2026Q2: 8,050,000 shares; 2026Q3: 7,025,000 shares 7,025,000$167M4.3%-1,025,000Timeline
TARSTARSUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 200,000 shares; 2026Q2: 1,050,000 shares; 2026Q3: 2,033,625 shares 2,033,625$160M4.13%+983,625Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 250,000 shares; 2025Q3: 1,160,000 shares; 2025Q4: 3,830,000 shares; 2026Q1: 3,250,000 shares; 2026Q2: 4,000,000 shares; 2026Q3: 3,225,000 shares 3,225,000$148M3.82%-775,000Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 140,000 shares; 2025Q3: 500,000 shares; 2025Q4: 735,000 shares; 2026Q1: 700,000 shares; 2026Q2: 1,550,000 shares; 2026Q3: 1,635,000 shares 1,635,000$107M2.77%+85,000Timeline
BCAXBICARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 710,000 shares; 2025Q1: 2,768,975 shares; 2025Q2: 5,000,000 shares; 2025Q3: 5,100,000 shares; 2025Q4: 3,575,000 shares; 2026Q1: 5,425,000 shares; 2026Q2: 5,250,000 shares; 2026Q3: 5,525,000 shares 5,525,000$103M2.66%+275,000Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 1,800,000 shares; 2025Q2: 727,500 shares; 2025Q3: 2,775,000 shares; 2025Q4: 120,000 shares; 2026Q1: 4,000,000 shares; 2026Q2: 3,375,000 shares; 2026Q3: 6,200,000 shares 6,200,000$99.9M2.58%+2,825,000Timeline
IMTXIMMATICS N.VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 6,275,000 shares; 2025Q1: 7,192,700 shares; 2025Q2: 6,250,000 shares; 2025Q3: 6,350,000 shares; 2025Q4: 6,125,000 shares; 2026Q1: 6,175,000 shares; 2026Q2: 6,175,000 shares; 2026Q3: 11,200,000 shares 11,200,000$98.3M2.54%+5,025,000Timeline
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 3,000,000 shares; 2025Q3: 5,500,000 shares; 2025Q4: 13,750,000 shares; 2026Q1: 18,000,000 shares; 2026Q2: 19,415,000 shares; 2026Q3: 18,045,000 shares 18,045,000$87.9M2.27%-1,370,000Timeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 425,000 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 800,000 shares; 2025Q4: 775,000 shares; 2026Q1: 3,603,465 shares; 2026Q2: 4,600,000 shares; 2026Q3: 7,130,000 shares 7,130,000$85.1M2.2%+2,530,000Timeline
GMEDGLOBUS MED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 325,000 shares; 2025Q1: 200,000 shares; 2025Q2: 500,000 shares; 2025Q3: 1,250,000 shares; 2025Q4: 1,275,000 shares; 2026Q1: 610,520 shares; 2026Q2: 850,000 shares; 2026Q3: 915,000 shares 915,000$68.5M1.77%+65,000Timeline
CBIOCRESCENT BIOPHARMA INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,500,000 shares; 2026Q1: 1,500,000 shares; 2026Q2: 1,630,000 shares; 2026Q3: 3,000,000 shares 3,000,000$43.8M1.13%+1,370,000Timeline
ZBHZIMMER BIOMET HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 50,000 shares; 2025Q3: not reported; 2025Q4: 150,000 shares; 2026Q1: 190,000 shares; 2026Q2: 1,400,000 shares; 2026Q3: 475,000 shares 475,000$42.2M1.09%-925,000Timeline
TVTXTRAVERE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 355,000 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 600,000 shares 600,000$35.3M0.91%newTimeline
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 250,000 shares; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,300,000 shares 1,300,000$33.6M0.87%newTimeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 810,000 shares; 2025Q1: 1,300,000 shares; 2025Q2: 2,000,000 shares; 2025Q3: 1,100,000 shares; 2025Q4: 600,000 shares; 2026Q1: 639,900 shares; 2026Q2: 700,000 shares; 2026Q3: 850,000 shares 850,000$31.6M0.82%+150,000Timeline
NKTRNEKTAR THERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 285,000 shares; 2026Q2: 1,000,000 shares; 2026Q3: 510,000 shares 510,000$30.9M0.8%-490,000Timeline
DRUGBRIGHT MINDS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 492,319 shares; 2026Q2: 545,000 shares; 2026Q3: 545,000 shares 545,000$27.2M0.7%0Timeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 400,000 shares 400,000$26.3M0.68%newTimeline
IMCRIMMUNOCORE HLDGS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 585,000 shares; 2026Q1: 2,766,868 shares; 2026Q2: 1,800,000 shares; 2026Q3: 850,000 shares 850,000$25.7M0.67%-950,000Timeline
PODDINSULET CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 50,601 shares; 2026Q2: 670,000 shares; 2026Q3: 175,000 shares 175,000$22.8M0.59%-495,000Timeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,166,504 shares; 2026Q2: 3,100,000 shares; 2026Q3: 1,495,000 shares 1,495,000$21.4M0.55%-1,605,000Timeline
SNYSANOFI SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 750,000 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,400,000 shares; 2026Q2: 2,000,000 shares; 2026Q3: 500,000 shares 500,000$20.6M0.53%-1,500,000Timeline
SVRASAVARA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 10,775,000 shares; 2025Q1: 11,000,000 shares; 2025Q2: 11,015,000 shares; 2025Q3: 4,015,000 shares; 2025Q4: 1,606,000 shares; 2026Q1: 2,600,052 shares; 2026Q2: 2,720,000 shares; 2026Q3: 3,300,000 shares 3,300,000$17M0.44%+580,000Timeline
SGPSPYGLASS PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 666,760 shares; 2026Q2: 670,000 shares; 2026Q3: 640,000 shares 640,000$16.6M0.43%-30,000Timeline
ZYMEZYMEWORKS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 185,000 shares; 2025Q1: 500,000 shares; 2025Q2: 1,150,000 shares; 2025Q3: 1,765,000 shares; 2025Q4: 865,000 shares; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 600,000 shares 600,000$15.9M0.41%newTimeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 3,000,000 shares; 2025Q2: 3,080,000 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,230,888 shares; 2026Q2: not reported; 2026Q3: 475,000 shares 475,000$15.2M0.39%newTimeline
SLDBSOLID BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,850,000 shares; 2025Q1: 1,753,558 shares; 2025Q2: 1,505,000 shares; 2025Q3: 2,975,000 shares; 2025Q4: 5,815,000 shares; 2026Q1: 5,000,000 shares; 2026Q2: 2,160,000 shares; 2026Q3: 2,085,000 shares 2,085,000$15.1M0.39%-75,000Timeline
LXEOLEXEO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,200,000 shares; 2025Q1: 1,136,249 shares; 2025Q2: 3,228,161 shares; 2025Q3: 3,250,000 shares; 2025Q4: 4,475,000 shares; 2026Q1: 4,475,000 shares; 2026Q2: 4,320,000 shares; 2026Q3: 4,320,000 shares 4,320,000$14.6M0.38%0Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 775,000 shares; 2026Q3: 800,000 shares 800,000$12.3M0.32%+25,000Timeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 200,000 shares; 2026Q2: 365,000 shares; 2026Q3: 395,000 shares 395,000$10.7M0.28%+30,000Timeline
EVMNEVOMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,000,000 shares; 2026Q3: 1,250,000 shares 1,250,000$10.3M0.27%+250,000Timeline
VKTXVIKING THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 914,147 shares; 2026Q2: 680,000 shares; 2026Q3: 290,000 shares 290,000$9.45M0.24%-390,000Timeline
STOKSTOKE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 345,000 shares 345,000$8.97M0.23%newTimeline
KRSAKORSANA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 263,105 shares 263,105$8.42M0.22%newTimeline
DMRADAMORA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 395,000 shares 395,000$8.41M0.22%newTimeline
TECXTECTONIC THERAPEUTIC INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 328,000 shares; 2026Q1: 328,000 shares; 2026Q2: 425,000 shares; 2026Q3: 360,000 shares 360,000$8.38M0.22%-65,000Timeline
ZURAZURA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 511,000 shares; 2026Q2: 1,173,956 shares; 2026Q3: 1,860,000 shares 1,860,000$7.74M0.2%+686,044Timeline
GKOSGLAUKOS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 45,000 shares 45,000$7.39M0.19%newTimeline
KLRAKAILERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 575,000 shares; 2026Q3: 625,000 shares 625,000$7.14M0.18%+50,000Timeline
AVRANTERIS TECHNOLOGIES GLOBALQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,144,780 shares; 2026Q2: 1,010,000 shares; 2026Q3: 850,000 shares 850,000$6.6M0.17%-160,000Timeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 200,000 shares; 2025Q2: 550,000 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 525,000 shares 525,000$6.14M0.16%newTimeline
RZLTREZOLUTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,686,000 shares; 2026Q1: not reported; 2026Q2: 382,999 shares; 2026Q3: 1,455,000 shares 1,455,000$6.02M0.16%+1,072,001Timeline
TRAXFIRST TRACKS BIOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,013,000 shares; 2026Q3: 169,738 shares 169,738$6.02M0.16%-843,262Timeline
VYGRVOYAGER THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,230,000 shares; 2025Q1: 1,249,418 shares; 2025Q2: 1,475,000 shares; 2025Q3: 1,475,000 shares; 2025Q4: 1,475,000 shares; 2026Q1: 3,002,936 shares; 2026Q2: 2,625,000 shares; 2026Q3: 2,165,000 shares 2,165,000$5.8M0.15%-460,000Timeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 175,000 shares 175,000$4.76M0.12%newTimeline
OLMAOLEMA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,650,000 shares; 2026Q1: 428,551 shares; 2026Q2: 418,551 shares; 2026Q3: 420,000 shares 420,000$3.63M0.09%+1,449Timeline
PALIPALISADE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,500,000 shares; 2026Q2: 2,500,000 shares; 2026Q3: 2,500,000 shares 2,500,000$3.38M0.09%0Timeline
ENGNENGENE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,667,430 shares; 2026Q3: 1,665,000 shares 1,665,000$3.33M0.09%-2,430Timeline
NGNENEUROGENE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 80,000 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 115,000 shares 115,000$3.2M0.08%newTimeline
IBIOIBIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,600,000 shares; 2026Q3: 2,600,000 shares 2,600,000$3.07M0.08%0Timeline
AVBPARRIVENT BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 100,000 shares 100,000$3.03M0.08%newTimeline
OKURONKURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 635,000 shares; 2025Q1: 635,000 shares; 2025Q2: 635,000 shares; 2025Q3: 635,000 shares; 2025Q4: 635,000 shares; 2026Q1: 1,839,819 shares; 2026Q2: 1,825,699 shares; 2026Q3: 1,088,000 shares 1,088,000$2.96M0.08%-737,699Timeline
CTMXCYTOMX THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 535,000 shares 535,000$1.46M0.04%newTimeline
OCSOCULIS HOLDING AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 132,000 shares 132,000$1.23M0.03%newTimeline
NYXHNYXOAH S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,924,216 shares; 2025Q1: 2,318,954 shares; 2025Q2: 1,402,002 shares; 2025Q3: 1,107,413 shares; 2025Q4: 1,107,000 shares; 2026Q1: 868,661 shares; 2026Q2: 843,461 shares; 2026Q3: 479,000 shares 479,000$661K0.02%-364,461Timeline
APREAPREA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 350,000 shares; 2026Q2: 350,000 shares; 2026Q3: 350,000 shares 350,000$262K0.01%0Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ABTABBOTT LABORATORIES1,400,000$127Mshares
AZNASTRAZENECA PLC450,000$85.3Mshares
RVMDREVOLUTION MEDICINES INC450,000$84.3Mshares
BCRXBIOCRYST PHARMACEUTICALS INC8,300,000$83Mshares
RGENREPLIGEN CORP400,000$54.6Mshares
BMYBRISTOL-MYERS SQUIBB CO800,000$46.1Mshares
QUREUNIQURE NV935,000$43.1Mshares
MDGLMADRIGAL PHARMACEUTICALS INC65,000$34.9Mshares
ALCALCON AG500,000$33.5Mshares
MYGNMYRIAD GENETICS INC5,735,000$32.7Mshares
RAPPRAPPORT THERAPEUTICS INC730,000$30.4Mshares
GEHCGE HEALTHCARE TECHNOLOGIES I450,000$28.8Mshares
BBNXBETA BIONICS INC1,600,000$25.1Mshares
REGNREGENERON PHARMACEUTICALS40,000$24.9Mshares
ANROALTO NEUROSCIENCE INC785,000$20.7Mshares
DMRADAMORA THERAPEUTICS INC575,000$15Mshares
SRZNSURROZEN INC304,669$7.91Mshares
MNPRMONOPAR THERAPEUTICS INC75,727$7.01Mshares
SGMTSAGIMET BIOSCIENCES INC535,452$4.14Mshares
TENXTENAX THERAPEUTICS INC53,439$778Kshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001974915-26-000008 base2026-11-16